article thumbnail

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases

Covalent Modifiers

Wherein JNK3 is specifically expressed in brain and emerges as therapeutic target, especially for neurodegenerative diseases. However, developing JNK3 selective inhibitors as chemical probes to investigate its therapeutic potential in diseases remains challenging.

article thumbnail

Site-Specific Molecular Glues for the 14-3-3/Tau pS214 ProteinProtein Interaction via Reversible Covalent Imine Tethering

Covalent Modifiers

Modulating PPIs with small molecules has gained increasing attention in drug discovery, particularly targeting the 14-3-3 protein family, which interacts with several hundred client proteins and plays a central role in cellular networks.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ALS drug effectively treats Alzheimer's disease in new animal study

Science Daily: Pharmacology News

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves neuron health in animal models of Alzheimer's disease, according to a new study.

article thumbnail

Researchers devise new way to target and correct disease-related proteins

Broad Institute

Related groups Xavier lab Over the past two decades, large genetic studies have linked tens of thousands of DNA variants to thousands of human traits and diseases. Yet, correcting the effects of those variants to treat disease has been hampered in part by the lack of precise molecular tools to do so.

Disease 139
article thumbnail

Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders

Covalent Modifiers

2025 , 147 , 25 , 21512–21525 [link] Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy for treating various diseases. However, current small molecule degraders predominantly rely on a limited set of E3 ubiquitin ligases, such as CRBN and VHL, which restricts their applications.

article thumbnail

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Covalent Modifiers

link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins. Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew.

article thumbnail

Golgi Neurosciences Partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment

Collaborative Drug

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.